SynthesisFrontiers in aging neuroscience2019
Benzodiazepines and Related Drugs as a Risk Factor in Alzheimer's Disease Dementia.
Synthesis in Frontiers in aging neuroscience, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 5 syntheses or guidelines pooled it, 73 citations in OpenAlex.
- Gabapentinoid Use and Risk of Alzheimer's Disease-Related Dementias: A Systematic Review and Meta-analysis of Observational Studies.Drugs & aging · 2026Pooled it
- Pharmacists' contribution to benzodiazepine deprescribing in older outpatients: a systematic review and meta-analysis.International journal of clinical pharmacy · 2023Pooled it
- Rationale for a Multi-Factorial Approach for the Reversal of Cognitive Decline in Alzheimer's Disease and MCI: A Review.International journal of molecular sciences · 2023Pooled it
- Pooled it
- Is there a link between the use of benzodiazepines and related drugs and dementia? A systematic review of reviews.European geriatric medicine · 2022Pooled it
- Benzodiazepine Dependence: Clinical and Molecular Aspects, Preventive Strategies and Therapeutic Approaches.International journal of molecular sciences · 2026Review
- Air pollution and Alzheimer's disease prevention: The science and a prevention plan.Journal of Alzheimer's disease : JAD · 2025Review
- Dreaming of Better Treatments: Advances in Drug Development for Sleep Medicine and Chronotherapy.Journal of sleep research · 2025Review
- Association between Benzodiazepine and Dementia Risk in Treating Depression after Breast Cancer Diagnosis: A Nationwide Population-Based Cohort Study.Yonsei medical journal · 2025Article
- Influence of Ageing on the Pharmacodynamics and Pharmacokinetics of Chronically Administered Medicines in Geriatric Patients: A Review.Clinical pharmacokinetics · 2025Review
- Medications and cognitive decline in Alzheimer's disease: Cohort cluster analysis of 15,428 patients.Journal of Alzheimer's disease : JAD · 2025Article
- Study on the relationship between insomnia disorder, PET/CT, and gut microbiota in patients with Alzheimer's disease.Frontiers in neurology · 2025Article
- The role of protein phosphorylation modifications mediated by iron metabolism regulatory networks in the pathogenesis of Alzheimer's disease.Frontiers in aging neuroscience · 2025Review
- Biomarkers of cognitive and memory decline in psychotropic drug users.Journal of neural transmission (Vienna, Austria : 1996) · 2025Review
- Medication Exposure and Risk of Dementia and Alzheimer's Disease.International journal of molecular sciences · 2024Review
- Neurexan Prescription Is Associated with Lower Risk of Sleep Disorder Recurrence and Depression Prevalence as Compared to Z-Drugs and Benzodiazepines: A Retrospective Database Analysis in Germany.Healthcare (Basel, Switzerland) · 2024Article
- Delirious Mania in a 77-Year-Old Female.Cureus · 2024Article
- Association Between Hypnotics and Dementia: A Mini Narrative Review.Psychiatry investigation · 2024Article
- Alzheimer's disease: a comprehensive review of epidemiology, risk factors, symptoms diagnosis, management, caregiving, advanced treatments and associated challenges.Frontiers in medicine · 2024Review
- [The exposome in the context of preventive measures for Alzheimer's and Parkinson's diseases].Der Nervenarzt · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 7 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Benzodiazepines (BZDs) and Z-drugs are compounds widely prescribed in medical practice due to their anxiolytic, hypnotic, and muscle relaxant properties. Yet, their chronic use is associated with cases of abuse, dependence, and relapse in many patients. Furthermore, elderly people are susceptible to alterations in pharmacodynamics, pharmacokinetics as well as to drug interaction due to polypharmacy. These situations increase the risk for the appearance of cognitive affectations and the development of pathologies like Alzheimer's disease (AD). In the present work, there is a summary of some clinical studies that have evaluated the effect of BZDs and Z-drugs in the adult population with and without AD, focusing on the relationship between their use and the loss of cognitive function. Additionally, there is an assessment of preclinical studies focused on finding molecular proof on the pathways by which these drugs could be involved in AD pathogenesis. Moreover, available data (1990-2019) on BZD and Z-drug use among elderly patients, with and without AD, was compiled in this work. Finally, the relationship between the use of BZD and Z-drugs for the treatment of insomnia and the appearance of AD biomarkers was analyzed. Results pointed to a vicious circle that would worsen the condition of patients over time. Likewise, it put into relevance the need for close monitoring of those patients using BZDs that also suffer from AD. Consequently, future studies should focus on optimizing strategies for insomnia treatment in the elderly by using other substances like melatonin agonists, which is described to have a much more significant safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.